Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-03-20
DOI
10.1093/neuonc/noac070
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions
- (2020) Patrick Y Wen et al. NEURO-ONCOLOGY
- Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor
- (2020) Kelly M. Hotchkiss et al. JOURNAL OF NEURO-ONCOLOGY
- Systemic Inflammatory Indicators as Prognosticators in Glioblastoma Patients: A Comprehensive Meta-Analysis
- (2020) Chao Yang et al. Frontiers in Neurology
- EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
- (2020) Michael Weller et al. Nature Reviews Clinical Oncology
- Landmark analysis: A primer
- (2019) Charity J. Morgan JOURNAL OF NUCLEAR CARDIOLOGY
- Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma
- (2019) Emilie Le Rhun et al. NEUROLOGY
- Neutrophil–lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival
- (2017) Matthew Mason et al. JOURNAL OF NEURO-ONCOLOGY
- Bone marrow response as a potential biomarker of outcomes in glioblastoma patients
- (2017) Eugene J. Vaios et al. JOURNAL OF NEUROSURGERY
- Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients
- (2017) Taiichi Saito et al. NEUROSURGICAL REVIEW
- Corticosteroids compromise survival in glioblastoma
- (2016) Kenneth L. Pitter et al. BRAIN
- Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
- (2016) W. Wick et al. CLINICAL CANCER RESEARCH
- Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment
- (2015) Giuseppe Lombardi et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors
- (2015) Stuart A. Grossman et al. Journal of the National Comprehensive Cancer Network
- Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
- (2015) L. Burt Nabors et al. NEURO-ONCOLOGY
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
- (2014) Roger Stupp et al. LANCET ONCOLOGY
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients
- (2013) Trine Zeeberg Iversen et al. OncoImmunology
- Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
- (2011) Stuart A. Grossman et al. CLINICAL CANCER RESEARCH
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
- (2010) J. H. Sampson et al. NEURO-ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors
- (2009) Terri S. Armstrong et al. NEURO-ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now